ERYTECH’s lead product candidate eryaspase, L-asparaginase encapsulated inside a donor-derived red blood cell, is a novel product candidate aimed at targeting cancer cells’ altered amino acid metabolism. L-asparaginase is well-established in the treatment of acute lymphoblastic leukemia, but toxicity has prevented its use in the most fragile patients and in other indications.
By encapsulating the L-asparaginase into red blood cells, eryaspase demonstrated the feasibility to enlarge its therapeutic window, and broaden the scope to other oncology indications such as hypersensitive ALL And pancreatic cancer.